Stockreport
Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patien...
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Agreement also enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once approved in Switzerland LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has reached an agreement with the Swiss Federal Office of Public Health (FOPH) and the Swiss Federal Social Insurance Office (FSIO) for the reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for eligible patients in Switzerland living with cystic fibrosis (CF).Under the terms of the agreement announced today, eligible patients ages two years and older with CF who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can be treated with ORKAMBI®. Eligible patients ages 12 years and older who either have two copies of the F508del mutation, or one copy of the F508del mutation and another responsive residual f
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | VRTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
VRTX alerts
VRTX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
NEWS
NEWS
- Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know [Yahoo! Finance][Yahoo! Finance]
- Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13[Business Wire]
- Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek [Yahoo! Finance][Yahoo! Finance]
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Scotiabank from $426.00 to $430.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
VRTX
SEC Filings
SEC Filings
- 12/20/24 - Form 8-K
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- VRTX's page on the SEC website
- More